Literature DB >> 10073723

Protection against experimental infection with group B streptococcus by immunization with a bivalent protein vaccine.

C Larsson1, M Stålhammar-Carlemalm, G Lindahl.   

Abstract

Group B streptococcus (GBS), a bacterium with polysaccharide capsule, is the major cause of sepsis and meningitis in early infancy. Recent work has indicated that immunity to GBS infection can be elicited by the surface proteins Rib and alpha, either of which is expressed by most GBS strains causing invasive infections. Here we show that a bivalent vaccine, composed of purified Rib and alpha mixed with aluminum hydroxide (alum), an adjuvant accepted for human use, elicits an antibody response to each of the two antigens. Moreover, the bivalent vaccine was found to protect against experimental infection with GBS strains representing the four classical serotypes. Our results represent an encouraging step towards the development of a human GBS vaccine based on pure protein antigens.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10073723     DOI: 10.1016/s0264-410x(98)00218-7

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  19 in total

1.  Localization of surface immunogenic protein on group B streptococcus.

Authors:  S Rioux; D Martin; H W Ackermann; J Dumont; J Hamel; B R Brodeur
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

2.  Surfome analysis as a fast track to vaccine discovery: identification of a novel protective antigen for Group B Streptococcus hypervirulent strain COH1.

Authors:  Francesco Doro; Sabrina Liberatori; Manuel J Rodríguez-Ortega; Cira D Rinaudo; Roberto Rosini; Marirosa Mora; Maria Scarselli; Emrah Altindis; Romina D'Aurizio; Maria Stella; Immaculada Margarit; Domenico Maione; John L Telford; Nathalie Norais; Guido Grandi
Journal:  Mol Cell Proteomics       Date:  2009-04-28       Impact factor: 5.911

3.  Identification of group B streptococcal Sip protein, which elicits cross-protective immunity.

Authors:  B R Brodeur; M Boyer; I Charlebois; J Hamel; F Couture; C R Rioux; D Martin
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

4.  Association between low concentrations of antibodies to protein alpha and Rib and invasive neonatal group B streptococcal infection.

Authors:  C Larsson; M Lindroth; P Nordin; M Stålhammar-Carlemalm; G Lindahl; I Krantz
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2006-11       Impact factor: 5.747

5.  Clonal variability of group B Streptococcus among different groups of carriers in southern Israel.

Authors:  D Marchaim; S Efrati; R Melamed; L Gortzak-Uzan; K Riesenberg; R Zaidenstein; F Schlaeffer
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-07       Impact factor: 3.267

Review 6.  Surface proteins of Streptococcus agalactiae and related proteins in other bacterial pathogens.

Authors:  Gunnar Lindahl; Margaretha Stålhammar-Carlemalm; Thomas Areschoug
Journal:  Clin Microbiol Rev       Date:  2005-01       Impact factor: 26.132

7.  Molecular characterization of Streptococcus agalactiae isolated from pregnant women and newborns at the University of Gondar Comprehensive Specialized Hospital, Northwest Ethiopia.

Authors:  Mucheye Gizachew; Moges Tiruneh; Feleke Moges; Mulat Adefris; Zemene Tigabu; Belay Tessema
Journal:  BMC Infect Dis       Date:  2020-01-13       Impact factor: 3.090

8.  Antibody against surface-bound C5a peptidase is opsonic and initiates macrophage killing of group B streptococci.

Authors:  Q Cheng; B Carlson; S Pillai; R Eby; L Edwards; S B Olmsted; P Cleary
Journal:  Infect Immun       Date:  2001-04       Impact factor: 3.441

9.  Group B streptococcal surface proteins as targets for protective antibodies: identification of two novel proteins in strains of serotype V.

Authors:  T Areschoug; M Stålhammar-Carlemalm; C Larsson; G Lindahl
Journal:  Infect Immun       Date:  1999-12       Impact factor: 3.441

10.  Immunization with C5a peptidase or peptidase-type III polysaccharide conjugate vaccines enhances clearance of group B Streptococci from lungs of infected mice.

Authors:  Qi Cheng; Steven Debol; Hong Lam; Ron Eby; Lorri Edwards; Yury Matsuka; Stephen B Olmsted; P Patrick Cleary
Journal:  Infect Immun       Date:  2002-11       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.